Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lamotrigine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Lamotrigine. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-003223-30 Sponsor Protocol Number: HeMiLa Start Date*: 2017-08-14
    Sponsor Name:University Hospital Tübingen
    Full Title: Prophylactic treatment of hemiplegic migraine with Lamotrigine
    Medical condition: Familiar hemplegic migraine
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004342-41 Sponsor Protocol Number: LAM100034 Start Date*: 2005-04-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures
    Medical condition: Epilepsy -partial seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004901-18 Sponsor Protocol Number: LAM107844 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: Clinical Evaluation of lamotrigine in Epilepsy
    Medical condition: Epilepsy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004343-21 Sponsor Protocol Number: LAM100036 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
    Medical condition: Epilepsy - Primary genralised tonic clonic seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001317-15 Sponsor Protocol Number: BAL2-2006 Start Date*: 2006-05-09
    Sponsor Name:University of Oxford
    Full Title: BALANCE 2: Bipolar disorder:Antidepressant/Lamotrigine/ANtipsychotic Comparative Evaluation
    Medical condition: Bipolar depression.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001949-42 Sponsor Protocol Number: BRD50 Start Date*: 2005-09-08
    Sponsor Name:University College London
    Full Title: A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003405-26 Sponsor Protocol Number: NF1-EXCEL Start Date*: 2014-09-03
    Sponsor Name:Erasmus MC
    Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL)
    Medical condition: Neurofibromatosis type 1
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) DK (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005024-40 Sponsor Protocol Number: NPP100023 Start Date*: 2005-04-06
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIA...
    Medical condition: Painful Diabetic Neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004954-13 Sponsor Protocol Number: E2090-AS886-202 Start Date*: 2017-04-24
    Sponsor Name:Eisai Taiwan Inc.
    Full Title: A Multi-center, Randomized, Open-label, Parallel-group, Dose-titration, Add-on, Comparative Study in Evaluating the Efficacy and Safety of Zonisamide (Zonegran) and Lamotrigine (Lamictal) for Subje...
    Medical condition: Epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-004023-19 Sponsor Protocol Number: A0081046 Start Date*: 2006-05-25
    Sponsor Name:Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom
    Full Title: A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES
    Medical condition: Epilepsy; Patients with newly diagnosed partial seizures (with or without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061334 Partial seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) PT (Completed) ES (Completed) BE (Completed) IE (Completed) CZ (Completed) LT (Completed) DE (Completed) SK (Completed) IT (Completed) HU (Completed) FI (Completed) EE (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-004513-33 Sponsor Protocol Number: OCTUMI-02 Start Date*: 2008-05-08
    Sponsor Name:University of Oxford
    Full Title: Comparative Evaluation of QUEtiapine-Lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in patients with bipolar depression
    Medical condition: Bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005405-21 Sponsor Protocol Number: UMCN-AKF 07.06 Start Date*: 2008-01-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: The influence of Raltegravir (MK_0518) on the pharmacokinetics of single-dose Lamotrigine in healthy male subjects (GRANOLA)
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002055-15 Sponsor Protocol Number: J81J1100168007 Start Date*: 2014-01-28
    Sponsor Name:UNIVERSITY OF SASSARI
    Full Title: RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER P...
    Medical condition: BIPOLAR I MOOD DISORDERS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001217-17 Sponsor Protocol Number: Max-Planck-Institute of Psychiatry Start Date*: 2005-09-12
    Sponsor Name:Max-Planck-Institute of Psychiatry
    Full Title: Comparison of venlafaxine augmentation with lamotrigine, quetiapine, or placebo in treatment resistant depression
    Medical condition: Treatment resistant depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004878-15 Sponsor Protocol Number: LAM115376 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline K.K. (GSK)
    Full Title: A multi-center, uncontrolled, open-label, evaluation of lamotrigine monotherapy in adult subjects with newly diagnosed epilepsy or recurrent epilepsy (currently untreated).
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004872-31 Sponsor Protocol Number: SCA102833 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline
    Full Title: The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age
    Medical condition: Bipolar Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004938 Bipolar disorders HLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003784-94 Sponsor Protocol Number: MexLam Start Date*: 2022-01-20
    Sponsor Name:Rigshospitalet, department of Neurology
    Full Title: Treatment of Myotonia - Lamotrigine versus Namuscla
    Medical condition: Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10049841 Myotonia congenital LLT
    20.1 100000004850 10076440 Hyperkalemic periodic paralysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003309-24 Sponsor Protocol Number: 2013-562 Start Date*: 2013-10-28
    Sponsor Name:Grete Andersen
    Full Title: Lamotrigine as treatment of Myotonia
    Medical condition: Myotonia is a symptom seen certain inherited muscle dystrophies and pure channelopathies (Dystrophia myotonica type 1 and 2, Myotonia Congenita, Paramyotonia Congenita, Hyperkalæmisk periodic paral...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061533 Myotonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001514-29 Sponsor Protocol Number: LAM115377 Start Date*: 2017-08-11
    Sponsor Name:GlaxoSmithKline KK
    Full Title: A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents
    Medical condition: Typical absence seizure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014665 10000331 Absence seizure LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 04:52:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA